Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients.
The role of stem cell therapy in multiple sclerosis: An overview of the current status of the clinical studies.
Novartis announces Russian regulatory approval for Gilenya®, a once-daily oral multiple sclerosis therapy and first in a new class
Three-Month Test-Retest Reliability of Center of Pressure Motion During Standing Balance in Individuals with Multiple Sclerosis.
Rapid, sustained and reversible pharmacodynamics of DAC HYP in MS patients supports mechanism of action via modulation of the IL-2 pathway
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Defining the Role of Physiotherapy in Palliative Care in Multiple Sclerosis.
In Vivo Maintenance of Human Regulatory T Cells during CD25 Blockade.
Reassessing the risk of natalizumab-associated PML.
The endocannabinoid system and multiple sclerosis.
Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus.
Akt Regulates Axon Wrapping and Myelin Sheath Thickness in the PNS.
Optimal combination of FLAIR and T2-weighted MRI for improved lesion contrast in multiple sclerosis.
The role of global and regional gray matter volume decrease in multiple sclerosis.
Clinically isolated syndromes: a new oligoclonal band test accurately predicts conversion to MS.
Moving Targets for Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.
Rare MEFV variants are not associated with risk to develop multiple sclerosis and severity of disease.
BRIEF: Teva files for Copaxone-Laquinimod patent
12-oxo-phytodienoic acid, a plant-derived oxylipin, attenuates lipopolysaccharide-induced inflammation in microglia.
A monoclonal natural human IgM protects axons in the absence of remyelination.
New data reinforce efficacy of TECFIDERA® (dimethyl fumarate) in MS patients with high disease activity
An Exploratory Investigation of Social Stigma and Concealment in Patients with Multiple Sclerosis.
Genzyme’s once-daily, oral AUBAGIO® (teriflunomide) approved in Argentina for the treatment of relapsing multiple sclerosis
Eosinophilic Fasciitis-like Disorder Developing in the Setting of Multiple Sclerosis Therapy.
Interferon β-secreting mesenchymal stem cells combined with minocycline attenuate experimental autoimmune encephalomyelitis.

Pages